Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080962 | 1.00 | OPRM1 (0.37) | OPRM1MAOBMAOASLC6A2SLC6A3 | |
| SCHEMBL13224947 | 1.00 | OPRM1 (0.37) | OPRM1MAOBMAOASLC6A2SLC6A3 | |
| SCHEMBL6003460 | 1.00 | OPRM1 (0.37) | OPRM1MAOBMAOASLC6A2SLC6A3 | |
| SCHEMBL29914544 | 0.83 | PNMT (0.33) | KMT2A | |
| SCHEMBL13224856 | 0.83 | PTGS2 (0.36) | OPRM1MAOBMAOA | |
| SCHEMBL13224854 | 0.83 | PTGS2 (0.36) | OPRM1MAOBMAOA | |
| SCHEMBL13224837 | 0.83 | PTGS2 (0.36) | OPRM1MAOBMAOA | |
| SCHEMBL8927314 | 0.83 | PTGS2 (0.36) | OPRM1MAOBMAOA | |
| SCHEMBL4402453 | 0.83 | PTGS2 (0.36) | OPRM1MAOBMAOA | |
| SCHEMBL18346581 | 0.83 | CCR2 (0.35) | CCR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | claimed |
| EP-2016053-B1 | PROCESS FOR THE SYNTHESIS OF (+) AND (-)-1-ARYL-3-AZABICYCLO[3.1.0]HEXANES | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2007127421-A2 | PROCESS FOR THE SYNTHESIS OF (+) AND (-)-1-ARYL-3-AZABICYCLO[3.1.0]HEXANES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | OPRM1 173/4885MAOB 2096/4885MAOA 1725/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | OPRM1 279/4885MAOB 22/4885MAOA 71/4885 |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | ADH1C, AVPR1B, HTR1B | OPRM1 34/4885MAOB 14/4885MAOA 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.